ASMase+/+mice. that were reversed by chloroquine to disrupt autophagy. The regulation of LC by U18666A or 25-hydroxycholesterol did not impact total mobile sphingomyelin content or its lysosomal circulation. Of relevance, amitriptyline-induced ASMase inhibition in human hepatocytes caused LC accumulation, impaired mitophagy and increased susceptibility to APAP. Similar results were observed upon glucocerebrosidase inhibition by conduritol -epoxide, a cellular model of Gaucher disease. These findings indicate that LC build up determines susceptibility to APAP hepatotoxicity by modulating mitophagy, and imply that genetic or drug-mediated ASMase disruption sensitizes to APAP-induced liver damage. Acetaminophen (APAP), a widely used pain reliever, is a dose-dependent hepatotoxin and a major reason for acute liver failure1, 2 . The metabolism of APAP to the reactive metabolite N-acetyl-p-benzo-quinoneimine (NAPQI) activates hepatocellular death following joining of NAPQI to mitochondrial protein thiols, mitochondrial JNK translocation, induction of mitochondrial permeability pore transition (MPT), generation of reactive o2 species (ROS) and ATP depletion3, 4, 5, 6, 7, eight. These occasions are prevented if enough GSH is available to detoxify NAPQI. Provided the crucial part of mitochondria in APAP-induced hepatotoxicity, selective removal of broken mitochondria is critical to limit liver damage. Macroautophagy (also referred because autophagy) is actually a catabolic process that degrades cellular protein and broken organelles through the fusion of autophagosomes with lysosomes to get the degradation of freight contents, including damaged mitochondria in a process called mitophagy9, 10, eleven. Recent findings indicated that APAP overdose induces autophagy in both primary cultured mouse hepatocytes and in the mouse liver. Pharmacological induction of autophagy by rapamycin protects against APAP-induced hepatotoxicity12, 13, and the proposed mechanism of safety was the removal of APAP-induced broken mitochondria. Lysosomes constitute the primary degradative compartment of the cell that maintain cellular homeostasis and physiological processes14. TSC1 However , very little is known about the role of lysosomes in APAP hepatotoxicity. Lysosomes have already been involved in APAP-induced liver damage by a mechanism inducing MPT via lysosomal iron mobilization15. Moreover, APAP causes lysosomal instability and cathepsin W release; however , this pathway does not seem to Taurodeoxycholate sodium salt play a substantial role in APAP hepatotoxicity16. Acid sphingomyelinase (ASMase) plays an important part in lysosomal membrane turnover through the hydrolysis of sphingomyelin, which results in ceramide generation. ASMase deficiency causes the lysosomal storage disease (LSD) Niemann-Pick type A (NPA), which is characterized mainly by sphingomyelin accumulation and a secondary increase in cholesterol in lysosomes of affected organs (e. g. brain, spleen and liver)17. An growing role of ASMase in autophagy have been recently described18. Cells deficient in ASMase exhibit impaired autophagic flux, increased LC3BII levels and enhanced p62 content19, 20. Moreover, ASMase deficiency helps prevent lysosomal membrane permeabilization caused by palmitic acid solution and protects against steatohepatitis19, 21. Here we show that lysosomal cholesterol (LC) accumulation by ASMase deficiency or glucocerebrosidase inhibition by conduritol -epoxide (CBE), a chemical induce of Gaucher disease (GD)22, exacerbates APAP hepatotoxicity by impairing mitophagy. Importantly, human being hepatocytes cured with amitriptyline, a tricyclic antidepressant that Taurodeoxycholate sodium salt inhibits ASMase23, exhibit LC accumulation, impaired Taurodeoxycholate sodium salt mitophagy and sensitization to APAP-induced cell death. These findings imply that patients with genetic or pharmacological jeopardized ASMase activity may be more sensitive to APAP-mediated liver failure. == Results == == ASMase deficiency lowers the threshold for APAP hepatoxicity == Serum BETAGT levels were elevated 24 h after APAP operations (300 mg/kg) in over night fasted ASMase+/+mice, but this increase was 3-fold higher in ASMase/mice (Fig. 1a). H&E and TUNEL staining of liver sections following APAP treatment revealed increased liver damage in ASMase/mice compared to ASMase+/+littermates (Fig. 1a, b). The increased susceptibility of ASMase/mice was managed at 200 mg/Kg APAP dose and also observed at lower APAP doses (75150 mg/kg), which do not cause damage in ASMase+/+litermates (Fig. 1c). Importantly, the rate of hepatocyte regeneration because evidenced by PCNA.